Psilocybin and Cannabis Affect the Brain Differently

Psilocybin and cannabis are increasingly discussed in the same conversations about alternative medicine, mental health, and emerging therapeutic research. Both have also attracted growing scientific interest for their potential to help people living with conditions such as anxiety, depression, chronic pain, and post-traumatic stress disorder.

However, while they are often mentioned side by side, scientists are continuing to uncover important differences in how these compounds interact with the brain. A 2026 study¹ offers fresh insight into what happens during a person’s first experience with psilocybin, revealing findings that could reshape how researchers think about psychedelic therapies and how they compare with cannabis. Let’s dive into the research and explore what the findings could mean for the future of cannabis and psychedelic science.

How Psilocybin and Cannabis Affect the Brain

While cannabis and psilocybin are often grouped together because both originate from naturally occurring compounds and are being investigated for therapeutic applications, they interact with entirely different biological systems.

Psilocybin primarily works by activating serotonin 5-HT2A receptors, which play important roles in perception, cognition, mood, and conscious awareness. Activation of these receptors is believed to temporarily reorganize communication between brain networks, producing the profound alterations in perception and thought that characterize psychedelic experiences.

Cannabis, on the other hand, works differently. THC, the primary psychoactive cannabinoid in cannabis, produces its effects mainly by activating CB1 receptors within the body’s endocannabinoid system. This signaling network helps regulate pain perception, appetite, memory, mood, stress responses, movement, and numerous other physiological functions. Rather than acting through serotonin receptors, THC modifies the release of many different neurotransmitters indirectly through endocannabinoid signaling.

What the Study Found

The study¹, published in Nature Communications, examined 28 healthy adults who had never used psychedelic drugs. Each participant received both doses in a fixed order: a 1-milligram control dose first, followed four weeks later by a 25-milligram dose. Researchers then used electroencephalography (EEG) to measure brain activity shortly after dosing and magnetic resonance imaging (MRI) to evaluate structural and functional brain changes over the following month. They also assessed psychological insight, cognitive flexibility, and overall well-being.

One of the most striking findings involved a measure known as brain-signal entropy. Entropy, in this context, refers to the complexity and unpredictability of brain activity. Higher entropy suggests that the brain is temporarily operating in a more flexible and less constrained state, potentially allowing new patterns of thinking and perception to emerge. Participants who received the 25-milligram dose experienced a significant increase in cortical signal entropy during the acute psychedelic experience, while the placebo group experienced no changes.

Additionally, the larger increases predicted greater improvements in psychological well-being one month later. The researchers also found that psychological insight experienced the day after treatment appeared to help explain the relationship between the temporary brain changes and longer-term improvements in well-being.

Brain Entropy Sets Psilocybin Apart

Perhaps the most intriguing aspect of the research is that the temporary increase in brain-signal entropy appears to distinguish psilocybin from what researchers have observed with THC. The increased entropy measured during the psychedelic experience predicted later psychological insight and improved well-being, suggesting that this temporary period of heightened brain flexibility may contribute to psilocybin’s therapeutic potential.

Current evidence suggests that moderate-to-high doses of THC does not produce the same pronounced entropy response. This does not mean cannabis lacks therapeutic value. Rather, it indicates that cannabis may achieve potential benefits through different biological mechanisms. Cannabis research has demonstrated effects on pain signaling, inflammation, stress regulation, sleep, memory processing, emotional regulation, and endocannabinoid balance. These mechanisms differ considerably from the temporary increases in brain complexity observed following psilocybin administration. Understanding these distinctions allows researchers to ask more precise questions about how each therapy might be used most effectively.

What This Means for Cannabis Research

The new findings reinforce an important principle for both researchers and healthcare professionals, as we now know that psychedelic therapies and cannabinoid therapies should not be treated as interchangeable simply because they are investigated for some of the same medical conditions. Depression, anxiety, chronic pain, post-traumatic stress disorder, and substance use disorders all involve multiple biological pathways, and different therapies may improve similar symptoms while acting through entirely separate neurological mechanisms.

Psilocybin appears to produce a brief period of heightened brain flexibility that may facilitate psychological insight when administered in carefully controlled clinical settings. The therapeutic model typically involves one or a few supervised dosing sessions combined with psychological preparation and integration.

Cannabis generally follows a very different treatment model. Patients often use cannabinoid-based medicines repeatedly over longer periods, with dosing individualized according to symptoms, cannabinoid composition, route of administration, and patient response. Rather than inducing profound alterations in consciousness, medical cannabis treatments are intended to support symptom management while allowing individuals to continue normal daily activities.

These differences also extend beyond dosing schedules. The subjective experiences, receptor targets, duration of action, therapeutic goals, and potential risks differ substantially between cannabinoids and psychedelics. As a result, evidence supporting one approach cannot automatically be applied to the other. Recognizing these differences will help researchers design better clinical trials and may ultimately lead to more personalized treatment strategies.

Expanding the Science Responsibly

Research into both cannabis and psilocybin continues to accelerate, but scientists increasingly recognize that each deserves to be studied on its own scientific merits.

The psilocybin findings provide valuable insight into how temporary changes in brain activity may contribute to lasting improvements in psychological well-being. At the same time, they highlight that similar therapeutic outcomes do not necessarily arise from similar biological processes. For cannabis researchers, this distinction is particularly valuable. Rather than comparing cannabinoids directly to psychedelics, future studies can focus on understanding the unique contributions of cannabinoids to the endocannabinoid system for specific therapeutic purposes.

As the evidence base grows, it is becoming increasingly clear that alternative medicine is not a single category of treatments operating through shared mechanisms. Instead, it encompasses a diverse collection of compounds that influence the brain and body in remarkably different ways. The future of precision medicine may depend not on grouping these therapies together, but on understanding exactly what makes each one unique.

References:

^{1. Lyons, T., Spriggs, M., Kerkelä, L. et al. Human brain changes after first psilocybin use. Nat Commun 17, 3977 (2026). https://doi.org/10.1038/s41467-026-71962-3}